Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
Scilex Holding Company (NASDAQ: SCLX) has appealed a lower court decision to the U.S. Court of Appeals for the Federal Circuit regarding its patent infringement lawsuit against Aveva Drug Delivery Systems. The case stems from May 2022, when Aveva submitted an Abbreviated New Drug Application (ANDA) to the FDA with a Paragraph IV notice concerning Scilex's ZTlido patents.
Initially filed in June 2022 at the U.S. District Court for the Southern District of Florida, the lawsuit alleged infringement of Scilex's Orange Book-listed patents for ZTlido. Following a trial in July 2024, the District Court ruled that Aveva's proposed product did not infringe Scilex's patents. The company is now vigorously pursuing an appellate review, with CEO Jaisim Shah expressing confidence in the strength of ZTlido's intellectual property portfolio.
Scilex Holding Company (NASDAQ: SCLX) ha fatto appello contro una decisione di un tribunale di primo grado presso la Corte d'Appello degli Stati Uniti per il Circuito Federale riguardo alla sua causa per violazione di brevetto contro Aveva Drug Delivery Systems. Il caso risale a maggio 2022, quando Aveva ha presentato una Domanda Abbreviata di Nuovo Farmaco (ANDA) alla FDA con un avviso di Paragrafo IV riguardante i brevetti ZTlido di Scilex.
Inizialmente presentata a giugno 2022 presso il Tribunale Distrettuale degli Stati Uniti per il Distretto Meridionale della Florida, la causa sosteneva la violazione dei brevetti di Scilex elencati nell'Orange Book per ZTlido. Dopo un processo a luglio 2024, il Tribunale Distrettuale ha stabilito che il prodotto proposto da Aveva non violava i brevetti di Scilex. L'azienda sta ora perseguendo con vigore una revisione in appello, con il CEO Jaisim Shah che esprime fiducia nella solidità del portafoglio di proprietà intellettuale di ZTlido.
Scilex Holding Company (NASDAQ: SCLX) ha apelado una decisión de un tribunal inferior ante el Tribunal de Apelaciones de los Estados Unidos para el Circuito Federal en relación con su demanda por infracción de patente contra Aveva Drug Delivery Systems. El caso se originó en mayo de 2022, cuando Aveva presentó una Solicitud Abreviada de Nuevo Medicamento (ANDA) a la FDA con un aviso de Párrafo IV respecto a las patentes ZTlido de Scilex.
Inicialmente presentada en junio de 2022 ante el Tribunal de Distrito de los Estados Unidos para el Distrito Sur de Florida, la demanda alegaba la infracción de las patentes de Scilex listadas en el Orange Book para ZTlido. Tras un juicio en julio de 2024, el Tribunal de Distrito dictaminó que el producto propuesto por Aveva no infringía las patentes de Scilex. La empresa ahora está persiguiendo con vigor una revisión de apelación, con el CEO Jaisim Shah expresando confianza en la solidez del portafolio de propiedad intelectual de ZTlido.
Scilex Holding Company (NASDAQ: SCLX)는 Aveva Drug Delivery Systems에 대한 특허 침해 소송과 관련하여 하급 법원의 결정을 미국 연방 순회 항소법원에 항소했습니다. 이 사건은 2022년 5월에 시작되었으며, Aveva는 Scilex의 ZTlido 특허에 관한 제4항 통지와 함께 FDA에 약물신청서(ANDA)를 제출했습니다.
2022년 6월 미국 플로리다 남부 지방법원에 처음으로 제기된 이 소송은 ZTlido에 대한 Scilex의 오렌지 북에 등재된 특허 침해를 주장했습니다. 2024년 7월 재판 후, 지방법원은 Aveva의 제안된 제품이 Scilex의 특허를 침해하지 않는다고 판결했습니다. 현재 이 회사는 항소 심리를 강력히 추진하고 있으며, CEO Jaisim Shah는 ZTlido의 지적 재산 포트폴리오의 강력함에 대한 자신감을 표명하고 있습니다.
Scilex Holding Company (NASDAQ: SCLX) a fait appel d'une décision d'un tribunal inférieur auprès de la Cour d'appel des États-Unis pour le circuit fédéral concernant sa poursuite pour violation de brevet contre Aveva Drug Delivery Systems. L'affaire remonte à mai 2022, lorsque Aveva a soumis une Demande Abbrégée de Nouveau Médicament (ANDA) à la FDA avec un avis de Paragraphe IV concernant les brevets ZTlido de Scilex.
Initialement déposée en juin 2022 auprès du tribunal de district des États-Unis pour le district sud de la Floride, la poursuite allègue une violation des brevets de Scilex inscrits dans l'Orange Book pour ZTlido. À l'issue d'un procès en juillet 2024, le tribunal de district a statué que le produit proposé par Aveva ne violait pas les brevets de Scilex. L'entreprise poursuit maintenant vigoureusement une révision en appel, le PDG Jaisim Shah exprimant sa confiance dans la solidité du portefeuille de propriété intellectuelle de ZTlido.
Scilex Holding Company (NASDAQ: SCLX) hat gegen eine Entscheidung eines unteren Gerichts beim US-Berufungsgericht für den Bundesgerichtshof Berufung eingelegt, die sich auf ihre Klage wegen Patentverletzung gegen Aveva Drug Delivery Systems bezieht. Der Fall geht auf Mai 2022 zurück, als Aveva einen Abgekürzten Neuen Arzneimittelantrag (ANDA) bei der FDA mit einer Paragraph-IV-Mitteilung bezüglich der ZTlido-Patente von Scilex einreichte.
Die Klage wurde ursprünglich im Juni 2022 beim US-Bezirksgericht für den südlichen Distrikt von Florida eingereicht und behauptete eine Verletzung der von Scilex im Orange Book aufgeführten Patente für ZTlido. Nach einem Prozess im Juli 2024 entschied das Bezirksgericht, dass das vorgeschlagene Produkt von Aveva die Patente von Scilex nicht verletzte. Das Unternehmen verfolgt nun energisch eine Berufungsprüfung, wobei CEO Jaisim Shah Vertrauen in die Stärke des geistigen Eigentumsportfolios von ZTlido äußert.
- Company has additional ZTlido patents pending for follow-on programs
- Multiple layers of intellectual property protection for ZTlido franchise
- District Court ruled against SCLX, finding no patent infringement by Aveva
- Potential threat to ZTlido market exclusivity if appeal is unsuccessful
- Legal expenses continue as litigation extends through appeal process
Insights
Scilex is currently navigating a challenging patent litigation scenario that introduces significant uncertainty for its ZTlido franchise. The District Court's ruling that Aveva's proposed product doesn't infringe Scilex's patents represents a substantial setback in their efforts to protect market exclusivity. Patent appeals to the Federal Circuit typically have about a 25-30% success rate for overturning district court decisions, making this an uphill battle.
The Paragraph IV ANDA challenge is particularly significant as it directly threatens Scilex's market protection. If Scilex ultimately loses this appeal, Aveva could potentially receive FDA approval to market a competing lidocaine patch, which would likely impact Scilex's market share and pricing power for ZTlido. This type of litigation is common in the pharmaceutical industry, but the first-instance loss weakens Scilex's negotiating position.
The CEO's reference to "additional patents forthcoming" suggests a layered IP defense strategy that could provide secondary protection even if this specific appeal fails. This is a standard approach in pharmaceutical IP strategy—developing a patent estate with multiple layers of protection. However, the immediate concern remains focused on the patents currently being litigated, which appear vulnerable based on the district court's findings.
This patent challenge against Scilex's ZTlido product represents a common but significant threat in the pharmaceutical industry. ZTlido (lidocaine topical system 1.8%) is one of Scilex's key marketed products for post-herpetic neuralgia, and maintaining exclusivity is crucial for preserving its value proposition in the non-opioid pain management segment where the company focuses.
The litigation centers around Aveva's Abbreviated New Drug Application, which specifically challenges Scilex's Orange Book-listed patents. These challenges typically target the most commercially relevant patent protection and aim to bring generic alternatives to market before patent expiration. The initial court ruling against Scilex is concerning, as successful ANDA challenges can lead to premature generic entry and substantial revenue erosion.
While the immediate decision is unfavorable, Scilex's multi-layered patent strategy—including forthcoming patents mentioned by the CEO—may provide some insulation even if this specific appeal fails. For smaller specialty pharmaceutical companies like Scilex (with a market cap of approximately
PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease, reiterates that it has appealed a lower court decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and will continue to vigorously pursue its infringement action on appeal against Aveva Drug Delivery Systems, Inc. (“Aveva”).
In May 2022, Scilex received notice that a pharmaceutical maker, Aveva and its former related entities, Apotex Corp. and Apotex Inc. (collectively, the “Apotex Parties”), had submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (“FDA”) and had filed a Paragraph IV notice, alerting both the FDA and Scilex that the proposed product may infringe Scilex’s ZTlido patents that are listed in the FDA’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication (the FDA’s “Orange Book”). In response, Scilex filed a patent infringement lawsuit against those parties in June 2022, in the U.S. District Court for the Southern District of Florida (the “District Court”), alleging infringement of Scilex’s Orange Book-listed patents covering ZTlido. The Apotex parties were later dismissed from the lawsuit.
Following the trial in July 2024, the District Court found that the proposed product did not infringe Scilex’s patents. Scilex has appealed that decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC. Scilex intends to continue to vigorously pursue its infringement action on appeal.
“We remain steadfast in our belief in the strength and validity of our ZTlido intellectual property and that Aveva is infringing on our patents. In light of the Court’s decision, we are pursuing an appellate review at the U.S. Court of Appeals for the Federal Circuit as warranted. We firmly believe we have built a strong portfolio of intellectual property and that the ZTlido franchise is well protected on multiple levels. The infringement suit is ongoing, and we have additional patents that are forthcoming for the follow-on programs,” said Jaisim Shah, President and Chief Executive Officer of Scilex.
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com
For more information on ZTlido®, including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex Holding Company is headquartered in Palo Alto, California.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly-owned subsidiary of Scilex, is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.
Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the final outcome of the patent infringement lawsuit or the timing thereof, any additional patents that are forthcoming for the follow-on programs, Scilex’s proposed joint venture with IPMC Company and the potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease.
Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex’s ability to obtain and maintain proprietary protection for its products, technology and know-how and to prevent others from infringing on its proprietary rights, Scilex’s ability to consummate a joint venture or any other transaction with IPMC Company and develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2025 Scilex Holding Company All Rights Reserved.
